246 related articles for article (PubMed ID: 28538107)
1. Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation.
Aggarwal N
Expert Opin Drug Saf; 2018 Jun; 17(6):581-587. PubMed ID: 28538107
[TBL] [Abstract][Full Text] [Related]
2. A comparison of approaches to identify possible cases of local anesthetic systemic toxicity in the FDA Adverse Event Reporting System (FAERS) database.
Dagenais S; Scranton R; Joyce AR; Vick CC
Expert Opin Drug Saf; 2018 Jun; 17(6):545-552. PubMed ID: 29745266
[TBL] [Abstract][Full Text] [Related]
3. Incidence of adverse events attributable to bupivacaine liposome injectable suspension or plain bupivacaine for postoperative pain in pediatric surgical patients: A retrospective matched cohort analysis.
Cohen B; Glosser L; Saab R; Walters M; Salih A; Zafeer-Khan M; Rivas E; Zhang K; Schacham NY; Chodavarapu P; Essber H; Chelnick D; Raza S; Hanline C; Khoshknabi D; Yang D; Seif J; Chhabada S; Turan A
Paediatr Anaesth; 2019 Feb; 29(2):169-174. PubMed ID: 30521078
[TBL] [Abstract][Full Text] [Related]
4. Local Anesthetic Systemic Toxicity During Transversus Abdominis Plane Block With Liposomal Bupivacaine.
Boleyn J; Hardie K; Burt MR; Wieman S
Am Surg; 2023 Nov; 89(11):4252-4254. PubMed ID: 37840256
[TBL] [Abstract][Full Text] [Related]
5. Periarticular Liposomal Bupivacaine Injection Versus Intra-Articular Bupivacaine Infusion Catheter for Analgesia After Total Knee Arthroplasty: A Double-Blinded, Randomized Controlled Trial.
Smith EB; Kazarian GS; Maltenfort MG; Lonner JH; Sharkey PF; Good RP
J Bone Joint Surg Am; 2017 Aug; 99(16):1337-1344. PubMed ID: 28816893
[TBL] [Abstract][Full Text] [Related]
6. Exparel®: A New Local Anesthetic with Special Safety Concerns.
Burbridge M; Jaffe RA
Anesth Analg; 2015 Oct; 121(4):1113-1114. PubMed ID: 26378712
[No Abstract] [Full Text] [Related]
7. Impact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studies.
Baxter R; Bramlett K; Onel E; Daniels S
Clin Ther; 2013 Mar; 35(3):312-320.e5. PubMed ID: 23453403
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Bupivacaine for Pain Control After Anterior Cruciate Ligament Reconstruction: A Prospective, Double-Blinded, Randomized, Positive-Controlled Trial.
Premkumar A; Samady H; Slone H; Hash R; Karas S; Xerogeanes J
Am J Sports Med; 2016 Jul; 44(7):1680-6. PubMed ID: 27159290
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Randomized Study Comparing Bupivacaine Hydrochloride Versus Bupivacaine Liposome for Pain Management After Distal Radius Fracture Repair Surgery.
Alter TH; Liss FE; Ilyas AM
J Hand Surg Am; 2017 Dec; 42(12):1003-1008. PubMed ID: 28969978
[TBL] [Abstract][Full Text] [Related]
10. Compartment syndrome in a patient treated with perineural liposomal bupivacaine (Exparel).
Soberón JR; Sisco-Wise LE; Dunbar RM
J Clin Anesth; 2016 Jun; 31():1-4. PubMed ID: 27185666
[TBL] [Abstract][Full Text] [Related]
11. Bupivacaine liposome injectable suspension: a new approach to postsurgical pain.
Owen RT
Drugs Today (Barc); 2013 Aug; 49(8):475-82. PubMed ID: 23977664
[TBL] [Abstract][Full Text] [Related]
12. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting.
Dasta J; Ramamoorthy S; Patou G; Sinatra R
Curr Med Res Opin; 2012 Oct; 28(10):1609-15. PubMed ID: 22900785
[TBL] [Abstract][Full Text] [Related]
13. Extended release bupivacaine formulations for postoperative analgesia: an update.
Balocco AL; Van Zundert PGE; Gan SS; Gan TJ; Hadzic A
Curr Opin Anaesthesiol; 2018 Oct; 31(5):636-642. PubMed ID: 30074492
[TBL] [Abstract][Full Text] [Related]
14. Time to onset of analgesia following local infiltration of liposome bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover study.
Apseloff G; Onel E; Patou G
Int J Clin Pharmacol Ther; 2013 May; 51(5):367-73. PubMed ID: 23458225
[TBL] [Abstract][Full Text] [Related]
15. Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks.
Ilfeld BM; Viscusi ER; Hadzic A; Minkowitz HS; Morren MD; Lookabaugh J; Joshi GP
Reg Anesth Pain Med; 2015; 40(5):572-82. PubMed ID: 26204387
[TBL] [Abstract][Full Text] [Related]
16. The safety of liposome bupivacaine, a novel local analgesic formulation.
Viscusi ER; Sinatra R; Onel E; Ramamoorthy SL
Clin J Pain; 2014 Feb; 30(2):102-10. PubMed ID: 23446090
[TBL] [Abstract][Full Text] [Related]
17. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
18. Intraoperative Intracavernosal Liposomal Bupivacaine (Exparel) Injection Does Not Affect Systemic Hemodynamics.
Taniguchi H; Mulhall JP
J Sex Med; 2020 Mar; 17(3):526-530. PubMed ID: 31983668
[TBL] [Abstract][Full Text] [Related]
19. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain.
Ilfeld BM
Expert Opin Pharmacother; 2013 Dec; 14(17):2421-31. PubMed ID: 24147423
[TBL] [Abstract][Full Text] [Related]
20. Liposomal bupivacaine and clinical outcomes.
Tong YC; Kaye AD; Urman RD
Best Pract Res Clin Anaesthesiol; 2014 Mar; 28(1):15-27. PubMed ID: 24815964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
